MX2013014898A - Antagonistas de trpv4. - Google Patents

Antagonistas de trpv4.

Info

Publication number
MX2013014898A
MX2013014898A MX2013014898A MX2013014898A MX2013014898A MX 2013014898 A MX2013014898 A MX 2013014898A MX 2013014898 A MX2013014898 A MX 2013014898A MX 2013014898 A MX2013014898 A MX 2013014898A MX 2013014898 A MX2013014898 A MX 2013014898A
Authority
MX
Mexico
Prior art keywords
compounds
trpv4
relates
trpv4 antagonists
antagonists
Prior art date
Application number
MX2013014898A
Other languages
English (en)
Other versions
MX337440B (es
Inventor
Marlys Hammond
Mui Cheung
Tram H Hoang
Patrick Stoy
Carl Brooks
Hilary Schenck Eidam
Krista B Goodman
Mark A Hilfiker
Jaclyn R Patterson
Guosen Ye
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013014898(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2013014898A publication Critical patent/MX2013014898A/es
Publication of MX337440B publication Critical patent/MX337440B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

La presente invención se relaciona con compuestos de espirocarbamato de fórmula (I) en la cual R1, (R2)Y, R3, R4, X y A tienen los significados indicados en la especificación; la invención proporciona además composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de los mismos y se relaciona con el uso de estos compuestos como antagonistas de TRPV4 para tratar o prevenir condiciones asociadas con desequilibrio de TRPV4.
MX2013014898A 2011-06-17 2012-06-15 Antagonistas de trpv4. MX337440B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
PCT/US2012/042622 WO2013012500A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (2)

Publication Number Publication Date
MX2013014898A true MX2013014898A (es) 2014-03-21
MX337440B MX337440B (es) 2016-03-03

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014898A MX337440B (es) 2011-06-17 2012-06-15 Antagonistas de trpv4.

Country Status (38)

Country Link
US (1) US9187464B2 (es)
EP (2) EP2721016B1 (es)
JP (1) JP5969017B2 (es)
KR (1) KR101870003B1 (es)
CN (1) CN103732583B (es)
AR (1) AR086958A1 (es)
AU (1) AU2012284540B2 (es)
BR (1) BR112013032391B1 (es)
CA (1) CA2839743C (es)
CL (1) CL2013003602A1 (es)
CO (1) CO6821953A2 (es)
CR (1) CR20130671A (es)
CY (1) CY1117792T1 (es)
DK (1) DK2721016T3 (es)
DO (1) DOP2013000307A (es)
EA (1) EA023616B1 (es)
ES (2) ES2688733T3 (es)
HK (1) HK1195068A1 (es)
HR (1) HRP20160539T1 (es)
HU (1) HUE029594T2 (es)
IL (1) IL229872A (es)
JO (1) JO3154B1 (es)
MA (1) MA35184B1 (es)
ME (1) ME02416B (es)
MX (1) MX337440B (es)
MY (1) MY173521A (es)
PE (1) PE20141943A1 (es)
PL (1) PL2721016T3 (es)
PT (1) PT2721016E (es)
RS (1) RS54858B1 (es)
SG (1) SG195106A1 (es)
SI (1) SI2721016T1 (es)
SM (1) SMT201600150B (es)
TW (1) TWI538912B (es)
UA (1) UA113963C2 (es)
UY (1) UY34138A (es)
WO (1) WO2013012500A1 (es)
ZA (1) ZA201308816B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720546B1 (en) 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
WO2012174340A1 (en) * 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists
JPWO2013146754A1 (ja) 2012-03-27 2015-12-14 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
BR112018073700A2 (pt) * 2016-05-19 2019-02-26 Glaxosmithkline Intellectual Property (No. antagonista trpv4
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
PE20201184A1 (es) * 2017-11-01 2020-11-03 Bristol Myers Squibb Co Compuestos espirociclicos como moduladores del receptor farnesoide x
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
CA3180132A1 (en) 2020-04-30 2021-10-30 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
WO2022014707A1 (ja) * 2020-07-16 2022-01-20 ラクオリア創薬株式会社 眼疾患の治療薬としてのｔｒｐｖ４阻害薬
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061436A1 (fr) * 1998-05-26 1999-12-02 Chugai Seiyaku Kabushiki Kaisha Derives d'indole heterocycliques et derives de mono ou de di-azaindole
JP2007534624A (ja) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション ビアリールピペラジニル−ピリジン類縁体
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
WO2008092891A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 1-oxa-3-azaspiro(4.5)decan-2-one derivatives for the treatment of eating disorders
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
MX2010001486A (es) * 2007-08-09 2010-03-01 Abbott Lab Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
EP2312947B1 (en) 2008-07-25 2014-01-01 GlaxoSmithKline LLC Trpv4 antagonists
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
WO2012024183A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2720546B1 (en) * 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
WO2012174340A1 (en) 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists

Also Published As

Publication number Publication date
KR20140041733A (ko) 2014-04-04
AU2012284540A1 (en) 2013-04-04
CN103732583B (zh) 2015-12-23
BR112013032391B1 (pt) 2020-11-24
CA2839743C (en) 2017-03-28
NZ618221A (en) 2015-02-27
HK1195068A1 (zh) 2014-10-31
EP2721016A4 (en) 2014-10-08
TW201313705A (zh) 2013-04-01
HUE029594T2 (en) 2017-03-28
WO2013012500A1 (en) 2013-01-24
DK2721016T3 (en) 2016-06-06
SI2721016T1 (sl) 2016-06-30
CY1117792T1 (el) 2017-05-17
AU2012284540B2 (en) 2014-08-28
CA2839743A1 (en) 2013-01-24
CL2013003602A1 (es) 2014-07-04
IL229872A (en) 2017-03-30
JP5969017B2 (ja) 2016-08-10
ZA201308816B (en) 2015-02-25
EA023616B1 (ru) 2016-06-30
US20140121206A1 (en) 2014-05-01
US9187464B2 (en) 2015-11-17
UY34138A (es) 2013-01-03
EP3121177A1 (en) 2017-01-25
HRP20160539T1 (hr) 2016-06-17
MA35184B1 (fr) 2014-06-02
MX337440B (es) 2016-03-03
UA113963C2 (xx) 2017-04-10
EP2721016B1 (en) 2016-04-06
JO3154B1 (ar) 2017-09-20
RS54858B1 (sr) 2016-10-31
EA201490037A1 (ru) 2015-12-30
EP2721016A1 (en) 2014-04-23
JP2014518214A (ja) 2014-07-28
TWI538912B (zh) 2016-06-21
AR086958A1 (es) 2014-02-05
CO6821953A2 (es) 2013-12-31
EP3121177B1 (en) 2018-08-01
KR101870003B1 (ko) 2018-06-22
PL2721016T3 (pl) 2017-01-31
DOP2013000307A (es) 2014-06-01
ES2569193T3 (es) 2016-05-09
ES2688733T3 (es) 2018-11-06
PT2721016E (pt) 2016-06-06
BR112013032391A2 (pt) 2016-08-16
CR20130671A (es) 2014-02-04
SG195106A1 (en) 2013-12-30
MY173521A (en) 2020-01-30
ME02416B (me) 2016-09-20
CN103732583A (zh) 2014-04-16
SMT201600150B (it) 2016-07-01
PE20141943A1 (es) 2014-12-28

Similar Documents

Publication Publication Date Title
SG195106A1 (en) Trpv4 antagonists
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014MN02598A (es)
MX354102B (es) Derivados de bencimidazol-prolina.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
IN2014DN06869A (es)
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
GB201209587D0 (en) Therapeutic compounds
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2014014308A (es) Pirrolidino heterociclos.
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration